Blog postings will resume in early January 2025

 

Dear Grey Horizon readers, 

Thank you for your support of the blog over the past year.  Postings will resume in early January 2025. 

Lung adenocarcinoma with mucinous histology

 A recently completed study conducted amongst four academic institutions/cancer centres across the United States (Dana Farber/Brigham and Women's Cancer Center, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Massachusetts General Hospital), along with the University of Bologna in Italy have uncovered that "mucinous histology is seen in 10% of patients with lung carcinoma."  Further, the researchers determined that patients diagnosed with lung adenocarcinoma with mucinous histology, have never smoked.  These findings indicate the need to strongly consider mucinous histology in future lung cancer prognostications. 

To learn more about this study, click here. 

Source mentioned: 

Di Federico A, Hong L, Elkrief A, et al. Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors. Annals Of Oncology; Published online 2 December 2024. DOI: https://doi.org/10.1016/j.annonc.2024.11.014

Prevention and screening have been major contributors to saving lives among five cancer types

 A recent study published in JAMA Oncology focusing on mortality from breast, cervical, colorectal, lung, and prostate cancer indicates that cancer prevention and screening significantly contributes to reductions in death among these 5 cancer types.  According to Dr. Katrina Goddard, co-lead investigator for the study, "8 out of 10 deaths from these five cancers were averted over the past 45 years due to advances in prevention and screening."  Further, the study, looking at cancer mortality over 45 years (1975-2020) states that 5.94 million deaths were averted...[where] "prevention and screening interventions accounted for 4.75 million, or 80% of the averted deaths." 

To read more about this study, click here. 

Source mentioned: 

1. Goddard KAB, Feuer EJ, Mandelblatt JS, et al. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. JAMA Oncol. Dec. 5, 2024. DOI:10.1001/jamaoncol.2024.538Exit Disclaimer
   

Adding pembrolizumab to preoperative radiotherapy and surgery improves disease-free survival for patients with stage III soft tissue sarcomas of the extremity

 

Findings from the SU2C-SARC032 trial, conducted by the Sarcoma Alliance for Research through Collaboration (SARC) in 20 academic institutions across Australia, Canada, Italy, and the USA, was recently published in The Lancet.  Led by Professor David G. Kirsch of the Princess Margaret Cancer entre in Toronto, results from the trial indicated "improvement in disease-free survival with addition of preoperative and postoperative pembrolizumab to preoperative radiation therapy and surgical resection for patients with stage III undifferentiated pleomorphic sarcoma or liposarcoma in the extremity or limb girdle." 

To learn more about this trial, click here. 

Source mentioned: 

• Mowery YM, Ballman KV, Hong AM, et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. The Lancet; Published Online 12 November 2024: DOI: https://doi.org/10.1016/S0140-6736(24)01812-9
• Italiano A. Perioperative immunotherapy in soft tissue sarcomas. The Lancet; Published Online 12 November 2024. DOI: https://doi.org/10.1016/S0140-6736(24)02252-9